Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.00% | 40.92% | 59.67% | 56.33% | 68.93% |
| Total Depreciation and Amortization | -- | -- | -- | -82.63% | -60.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -119.79% | -80.96% | -94.96% | -77.79% | -93.48% |
| Change in Net Operating Assets | -300.69% | -281.89% | -24.43% | 162.54% | 84.15% |
| Cash from Operations | -2,270.99% | -1,075.51% | 64.83% | 80.82% | 83.78% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 89.70% | 174.12% | 148.94% | 148.42% | 315.97% |
| Total Debt Repaid | -100.00% | -100.00% | -- | 28.40% | 200.00% |
| Issuance of Common Stock | -- | 3,700.00% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -108.79% | -108.79% | -- | 200.00% | 200.00% |
| Cash from Financing | 1,988.43% | 1,898.11% | -62.18% | -129.81% | -82.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 202.65% | 181.82% | -- | -- | -- |
| Net Change in Cash | 121.62% | 96.47% | 106.76% | -1,775.00% | -324.24% |